Project Grant F30CA306185
Award Date 1/16/26
Completion Date 8/31/29
Dollars Obligated $109K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $827,942.00 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate a novel inhibitory receptor that regulates the persistence and function of chimeric antigen receptor (CAR)-engineered T cell therapy for lymphoma. The key objectives are to: 1) examine the causal role of this inhibitory receptor axis in impairing the therapeutic...
- The federal Project Grant award titled "HARNESSING B CELLS AFTER STEM CELL TRANSPLANT TO PRODUCE NOVEL CAR-TS" is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for a total of $415,257. The project period runs from July 3, 2025 to June 30, 2027. The award aims to leverage insights into B cell tolerance mechanisms after hematopoietic stem cell transplantation to engineer less toxic, more targeted immune cells that can eradicate hematological...
- This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
- This $1,313,567 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Cytoagents Inc., a Pittsburgh-based pharmaceutical company, in developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. CRS is a severe and potentially life-threatening immune-mediated toxicity that can occur with CAR T-cell treatments for hematologic malignancies. The...
- The University of Maryland, Baltimore received a $422,799 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on therapeutic targeting and biophysical characterization of chimeric antigen receptor (CAR)-mediated trogocytosis. The project aims to investigate the molecular basis of CAR-mediated trogocytosis, a mechanism of resistance to CAR T cell therapy, and explore alternative approaches to selectively inhibit this process and enhance...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $151,856 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the relationship between the hyper-thrombotic state and immunosuppression in glioblastoma (GBM), the most common primary malignant brain tumor. The research aims to: 1) investigate how GBM induces platelet hyperactivity and its impact on tumor growth, and 2)...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), will support an early-stage investigator at Case Western Reserve University (CWRU) to investigate the role of heme dysregulation in the innate and adaptive immune response of patients with sepsis or chronic hemolytic diseases. The $402,500 award, with a performance period from August 1, 2025 to July 31, 2030, aims to establish new...
- The National Institutes of Health, National Cancer Institute awarded a $140,433 Project Grant to The Leland Stanford Junior University under the Cancer Research Manpower (CFDA 93.398) program. The award will be used to generate CD19.28Z chimeric antigen receptor (CAR) T cells in vivo using a Programmable Antibody-mediated Cellular Knock-in of T cells (PACK-IT) system. The goals are to optimize the PACK-IT system, compare the resulting PACK-IT CAR-T cells to conventionally manufactured CAR-T...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $162,486 to Case Western Reserve University to study translation regulation in glioblastoma stem-like cells (GSCs) and their adaptation to hypoxic tumor environments. The research aims to gain a better understanding of GSC biology and the post-transcriptional regulatory mechanisms that enable them to thrive in both low and normal oxygen conditions, promoting glioblastoma tumor growth....
- This federal Project Grant award of $216,460 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) to Case Western Reserve University aims to understand the mechanisms through which the EGFR L858R mutation in lung cancer generates an immunogenic neoantigen that provokes T cell-mediated anti-tumor immunity. The research project will fully characterize the EGFR L858R-derived neopeptide and its ability to activate T cells, utilizing techniques such as HLA...